Zomedica expands TRUVIEW AI microscopy platform with new artificial intelligence (AI) diagnostic interpretation capabilities, significantly broadening its commercial scope and clinical utility. This enhancement, now deployed across the installed base, introduces automated hematology analysis and prepares the platform for forthcoming cytology support.

The update, delivered over the air through the myZomedica® ecosystem, requires no hardware upgrade for existing TRUVIEW® subscribers. The system’s AI now classifies blood cells, highlights abnormal findings, and returns actionable results within minutes, while offering optional telepathology reviews by certified specialists to support clinical certainty.

AI‑Driven Interpretation Improves Diagnostic Efficiency

With the integration of AI, TRUVIEW accelerates diagnostic workflows by automating interpretations once requiring manual review. The capability reduces turnaround times and supports consistency across high‑volume veterinary practices. Moreover, the system’s machine‑trained algorithms analyze complex cellular features, aiding in the detection of conditions such as anemia, infection, and coagulopathies.

This innovation positions the TRUVIEW platform as more than an automated slide preparation tool, evolving it into a full‑featured diagnostic system. It underscores Zomedica’s strategy to increase customer value and deepen clinical relevance in the competitive veterinary diagnostics market.

Strengthening Adoption and Market Potential

Zomedica expands TRUVIEW AI microscopy platform to address adoption barriers by enhancing workflow capabilities that matter most to veterinary professionals. Faster, standardized interpretations help practices improve patient care and operational efficiency. The software‑based nature of the upgrade supports capital‑efficient scaling and leverages the current TRUVIEW installed base to drive broader engagement.

Additionally, AI outputs integrate seamlessly into the myZomedica® platform, which facilitates centralized updates and optional expert review. Skin and ear cytology support remain under development, with expectations for imminent release.

Strategic Implications for Investors

Investors should note that this enhancement differentiates the TRUVIEW system in a market where diagnostic speed and consistency are critical decision drivers. By boosting platform capabilities without additional hardware costs, Zomedica reinforces potential margin expansion and operational leverage. The update aligns with the company’s long‑term vision to build an integrated suite of point‑of‑care veterinary diagnostic solutions.

Industry Reaction and Clinical Utility

Veterinary specialists acknowledge the growing role of AI in clinical decision support. AI‑assisted analysis, particularly for cytology, can reduce manual variability while improving diagnostic confidence. By advancing the platform’s analytical depth, Zomedica strengthens its value proposition for practices seeking modern, efficient diagnostics.

In sum, Zomedica expands TRUVIEW AI microscopy platform with intelligent diagnostic interpretation that enhances workflow speed, consistency, and clinical relevance. As software‑driven capabilities continue to evolve, the company is well positioned to capture a larger share of the veterinary diagnostics market and support better outcomes for animal health professionals.